Rentschler Biopharma marks construction milestone at new German buffer media facility
The new biopharmaceutical production facility represents the CDMO’s largest single investment at its headquarters in Lauphei, Germany.
List view / Grid view
The new biopharmaceutical production facility represents the CDMO’s largest single investment at its headquarters in Lauphei, Germany.
The move will boost its oncology pipeline, adding a potential first-in-class anti-BTN3A monoclonal antibody for acute myeloid leukaemia.
7 October 2025 | By Rapid Micro Biosystems
This webinar showcases a rapid microbial method that can help to address the time to result challenge posed by short shelf-life radiopharmaceuticals.
The company will instead focus its attention on advancing candidates for modalities that include biologics and ADCs.
uniQure’s positive topline data “are the most convincing in the field to date” and indicate the gene therapy’s potential disease-modifying effects.
The right packaging is critical when it comes to preserving the quality, efficacy and safety of pharmaceutical and nutraceutical products. Here, Uwe Raupbach, R&D Engineer Desiccants, Sanner GmbH, answers some key questions about the need for environmental management in packaging, focusing on moisture and odour control, and the solutions available…
EPR Issue 3 includes articles on microbiology, downstream processing, manufacturing, drug formulation and more.
The new $5 billion manufacturing site is set to become the company’s first integrated facility for API and drug product manufacturing.
2 September 2025 | By FUJIFILM Wako Europe GmbH
Join this webinar to find out how RT-rt PCR is revolutionising sterility testing and discover a unique approach that provides reliable one-day results and enhanced sensitivity and detection capabilities.
Contracts to use a facility at Fujifilm’s North Carolina site as part of moves to onshore its manufacturing.
The Australian biotech's new operating model will also see medical and commercial functions at its CSL Behring and CSL Vifor units combined.
The EMA’s decision permits WuXi Biologics to progress with commercial manufacturing of a global client’s innovative biologic.
In this article, Miguel Angel Ortega Sánchez of ROIS explores how the industry is adapting to new delivery formats, device bottlenecks, and strategic partnership models — and why flexibility, compliance, and tech transfer agility are now critical to success.
Becomes the first monoclonal antibody for the condition to be approved by the MHRA and advances the pharma company’s ambitions in diabetes.
15 August 2025 | By Bruker Microbiology & Infection Diagnostics
This webinar explores the benefits of accelerated microbial identification using MALDI-TOF in pharmaceutical contamination control strategies.